Bystander dendritic cell (DC)

Bystander dendritic cells (DCs) refer to a functional state of dendritic cells that undergo maturation and activation indirectly, typically through exposure to inflammatory cytokines such as Type I interferons (IFN-α/β) or tumor necrosis factor (TNF), rather than through direct recognition of pathogen-associated molecular patterns (PAMPs) via their own pattern recognition receptors (Source: PubMed, PMID: 11113122). This process, known as bystander activation, allows DCs that have not directly encountered a pathogen to upregulate co-stimulatory molecules like CD80 and CD86 and increase MHC class II expression, thereby enhancing the overall environment for T-cell priming and expansion (Source: Journal of Immunology, 2004). While this mechanism is vital for amplifying immune responses during viral infections, it carries the risk of promoting autoimmunity if these activated bystander DCs present self-antigens in a highly inflammatory context (Source: Nature Immunology, 2001). In therapeutic contexts, the modulation of the bystander DC state is of interest in vaccine development and cancer immunotherapy to broaden the immune repertoire, though the cells themselves are not a single molecular target. Because "Bystander dendritic cells" describes a cellular phenotype and physiological process rather than a specific protein, receptor, or enzyme, it does not meet the criteria for a conventional molecular therapeutic target.

Other names

Bystander DCIndirectly activated dendritic cellNon-antigen-bearing dendritic cellBystander-activated dendritic cell

Not applicable as this refers to a cellular state rather than a molecular target.